

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number  
WO 01/00185 A2(51) International Patent Classification<sup>7</sup>: A61K 31/00

(21) International Application Number: PCT/EP00/05541

(22) International Filing Date: 16 June 2000 (16.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9914745.6 24 June 1999 (24.06.1999) GB(71) Applicant (*for all designated States except US*): KNOLL  
AKTIENGESSELLSCHAFT [DE/DE]; D-67061 Lud-  
wigshafen (DE).


(72) Inventor; and

(75) Inventor/Applicant (*for US only*): KILPATRICK, Ian,  
Charles [GB/GB]; R3 Pennyfoot Street, Nottingham NG1  
1GF (GB).(74) Agent: DOERPER, Thomas; Basf Aktiengesellschaft,  
D-67056 Ludwigshafen (DE).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,  
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,  
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO,  
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published:

— Without international search report and to be republished  
upon receipt of that report.*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: THERAPEUTIC AGENTS




(I)

(57) Abstract: The present invention provides a method of treating obesity and related conditions comprising the administration to a mammal, particularly a human, in need thereof of a therapeutically effective amount of a compound of formula (I) in which: n=0, 1 or 2; R<sub>1</sub> and R<sub>2</sub> independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo); R<sub>3</sub> and R<sub>4</sub> independently represent H or alkyl of 1 to 4 carbon atoms; or together represent a group of formula =NR<sub>12</sub> where R<sub>12</sub> represents H, hydroxy, alkyl of 1 to 4 carbon atoms, a phenyl or alkoxy of 1 to 4 carbon atoms; each alkyl, phenyl and alkoxy being optionally substituted with one or more halo; R<sub>5</sub> represents: (a) H, (b) alkyl of 1 to 4 carbon atoms, (c) a group offormula-COR<sub>13</sub> in which R<sub>13</sub> represents H, alkyl of 1 to 4 carbon atoms or phenyl, when R<sub>3</sub> and R<sub>4</sub> represent H or alkyl (optionally substituted with one or more halo, or (d) or a group of formula -S(O)<sub>p</sub>R<sub>14</sub> in which p=1 or 2 and R<sub>14</sub> is alkyl of 1 to 4 carbon atoms or phenyl, when R<sub>3</sub> and R<sub>4</sub> represent H or alkyl (optionally substituted with one or more halo); each alkyl and phenyl being optionally substituted with one or more halo; R<sub>6</sub> and R<sub>7</sub> are each H; R<sub>8</sub> to R<sub>11</sub> independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof.

Therapeutic Agents

The present invention relates to the use of 2,3,4,5-tetrahydro-1,4-benzothiazepines in the treatment of obesity, eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, and as an aid to smoking cessation.

Compounds of formula I



10

in which:

$n = 0, 1 \text{ or } 2$ ;

$R_1$  and  $R_2$  independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo);

15  $R_3$  and  $R_4$  independently represent H or alkyl of 1 to 4 carbon atoms; or together represent a group of formula  $=NR_{12}$  where  $R_{12}$  represents H, hydroxy, alkyl of 1 to 4 carbon atoms, phenyl or alkoxy of 1 to 4 carbon atoms; each alkyl, phenyl and alkoxy being optionally substituted with one or more halo;

$R_5$  represents: (a) H, (b) alkyl of 1 to 4 carbon atoms, (c) a group of formula  $-COR_{13}$

20 in which  $R_{13}$  represents H, alkyl of 1 to 4 carbon atoms or phenyl, when  $R_3$  and  $R_4$  represent H or alkyl (optionally substituted with one or more halo, or (d) or a group of formula  $-S(O)_pR_{14}$  in which  $p = 1 \text{ or } 2$  and  $R_{14}$  is alkyl of 1 to 4 carbon atoms or phenyl, when  $R_3$  and  $R_4$  represent H or alkyl (optionally substituted with one or more halo); each alkyl and phenyl being optionally substituted with one or more halo;

25  $R_6$  and  $R_7$  are each H;

$R_8$  to  $R_{11}$  independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon


atoms), or sulphonamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof;

5 with the proviso that:

(i) when  $n = 0$ ; at least one of  $R_1$  to  $R_{11}$  is other than H;

are disclosed in WO94/11360 for the treatment of seizures and neurological disorders.

10 The present invention provides a method of treating obesity and related conditions comprising the administration to a mammal, particularly a human, in need thereof of a therapeutically effective amount of a compound of formula I



15

in which:

$n = 0, 1$  or  $2$ ;

$R_1$ , and  $R_2$  independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo);

20  $R_3$  and  $R_4$  independently represent H or alkyl of 1 to 4 carbon atoms; or together represent a group of formula  $=NR_{12}$  where  $R_{12}$  represents H, hydroxy, alkyl of 1 to 4 carbon atoms, phenyl or alkoxy of 1 to 4 carbon atoms; each alkyl, phenyl and alkoxy being optionally substituted with one or more halo;

$R_5$  represents: (a) H, (b) alkyl of 1 to 4 carbon atoms, (c) a group of formula  $-COR_{13}$


25 in which  $R_{13}$  represents H, alkyl of 1 to 4 carbon atoms or phenyl, when  $R_3$  and  $R_4$  represent H or alkyl (optionally substituted with one or more halo, or (d) or a group of formula  $-S(O)_pR_{14}$  in which  $p = 1$  or  $2$  and  $R_{14}$  is alkyl of 1 to 4 carbon atoms or phenyl, when  $R_3$  and  $R_4$  represent H or alkyl (optionally substituted with one or more halo); each alkyl and phenyl being optionally substituted with one or more halo;

R<sub>6</sub> and R<sub>7</sub> are each H;

- R<sub>8</sub> to R<sub>11</sub> independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each
- 5 alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof.

- 10 The term "related conditions" as used herein means eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, and as an aid to smoking cessation.

- 15 In a preferred group of compounds of formula I



n is 0 or 1;

- 20 R<sub>1</sub>, R<sub>2</sub>, R<sub>6</sub> and R<sub>7</sub> are each H;
- R<sub>3</sub> and R<sub>4</sub> are independently H or methyl; or together represent imino, methylimino, phenylimino, hydroxyimino or methoxyimino;
- R<sub>5</sub> is H or methyl, or when R<sub>3</sub> and R<sub>4</sub> are independently H or methyl, R<sub>5</sub> is H, methyl, formyl, acetyl, propionyl, benzoyl, methylsulphinyl, methylsulphonyl or
- 25 ethylsulphonyl;
- R<sub>8</sub> is H, methyl, fluoro or chloro; and
- R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub> are each H;
- or a pharmaceutically acceptable salt thereof.

Preferred compounds of formula I are selected from:

- 6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;
- 6-fluoro-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 5 4-formyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;
- 4-acetyl-6-fluoro-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 6-chloro-4-methylsulphinyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 10 4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;
- 4-ethylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 6-chloro-3-hydroxyimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 3-hydroxyimino-6-methyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 3-methylimino-2,3,4,5-tetrahydro-1,4-benzothiazepine; and
- 15 6-chloro-3-phenylimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- their stereoisomers; and pharmaceutically acceptable salts thereof.

More preferred compounds of formula I are selected from:

- 6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 20 6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;
- 6-fluoro-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 4-formyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 6-chloro-4-methylsulphinyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 25 6-chloro-3-hydroxyimino-2,3,4,5-tetrahydro-1,4-benzothiazepine; and
- 6-chloro-3-phenylimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- their stereoisomers; and pharmaceutically acceptable salts thereof.

Most preferred compounds of formula I are selected from:


- 30 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;
- 4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 6-chloro-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;
- 6-chloro-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide; and

6-fluoro-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
their stereoisomers; and pharmaceutically acceptable salts thereof.

A particularly preferred compound of formula I is:

- 5 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
its stereoisomers; and pharmaceutically acceptable salts thereof.

The present invention also provides pharmaceutical compositions for the  
treatment of obesity and related conditions comprising a therapeutically effective  
10 amount of compounds of formula I



in which:

$n = 0, 1 \text{ or } 2$ ;

- $R_1$ , and  $R_2$  independently represent H or alkyl of 1 to 4 carbon atoms (optionally  
15 substituted by one or more halo);

$R_3$  and  $R_4$  independently represent H or alkyl of 1 to 4 carbon atoms; or together  
represent a group of formula  $=NR_{12}$  where  $R_{12}$  represents H, hydroxy, alkyl of 1 to 4  
carbon atoms, phenyl or alkoxy of 1 to 4 carbon atoms; each alkyl, phenyl and alkoxy  
being optionally substituted with one or more halo;

- 20  $R_5$  represents: (a) H, (b) alkyl of 1 to 4 carbon atoms, (c) a group of formula  $-COR_{13}$   
in which  $R_{13}$  represents H, alkyl of 1 to 4 carbon atoms or phenyl, when  $R_3$  and  $R_4$   
represent H or alkyl (optionally substituted with one or more halo, or (d) or a group of  
formula  $-S(O)_pR_{14}$  in which  $p = 1 \text{ or } 2$  and  $R_{14}$  is alkyl of 1 to 4 carbon atoms or  
phenyl, when  $R_3$  and  $R_4$  represent H or alkyl (optionally substituted with one or more  
25 halo); each alkyl and phenyl being optionally substituted with one or more halo;

$R_6$  and  $R_7$  are each H;

$R_8$  to  $R_{11}$  independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms,  
alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy  
of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon

atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and

pharmaceutically acceptable salts thereof;

5 with the proviso that:

(i) when  $n = 0$ ; at least one of  $R_1$  to  $R_{11}$  is other than H;

together with a pharmaceutically acceptable diluent or carrier.

Preferred pharmaceutical compositions for the treatment of obesity and  
10 related conditions comprise a therapeutically effective amount of compounds of formula I in which:

$n = 0$  or 1;

$R_1$  and  $R_2$  are independently H or methyl;

$R_3$  and  $R_4$  are independently H or methyl; or together represent imino, methylimino,  
15 phenylimino, hydroxyimino or methoxyimino;

$R_5$  is H or methyl, and when  $R_3$  and  $R_4$  are H or methyl,  $R_5$  is H, methyl, formyl, acetyl, propionyl, benzoyl, methylsulphanyl, methylsulphonyl or ethylsulphonyl;

$R_6$  and  $R_7$  are each H; and

one of  $R_8$  to  $R_{11}$  is H, fluoro, chloro, bromo, iodo, methyl (optionally substituted with  
20 one or more halo), methoxy (optionally substituted by one or more halo), nitro, cyano, carboxy, acetyl, dimethylcarbamoyl or dimethylsulphamoyl; the remainder of  $R_8$  to  $R_{11}$  being H;

their stereoisomers; and

pharmaceutically acceptable salts thereof.

25

More preferred pharmaceutical compositions for the treatment of obesity and related conditions comprise a therapeutically effective amount of compounds of formula I in which:

$n = 0$  or 1;

30  $R_1$ ,  $R_2$ ,  $R_6$  and  $R_7$  are each H;

$R_3$  and  $R_4$  are H, or together are methylimino, phenylimino, hydroxyimino or methoxyimino;

R<sub>5</sub> is H or methyl, and when R<sub>3</sub> and R<sub>4</sub> are H, R<sub>5</sub> is H, methyl, formyl, acetyl, propionyl, benzoyl, methylsulphinyl, methylsulphonyl, or ethylsulphonyl;

R<sub>8</sub> is H, methyl, fluoro or chloro;

R<sub>9</sub> to R<sub>11</sub> are all H;

- 5 their stereoisomers; and  
pharmaceutically acceptable salts thereof.

Especially preferred pharmaceutical compositions for the treatment of obesity and related conditions comprise a therapeutically effective amount of compounds of  
10 formula I selected from:

- 6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;  
6-fluoro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
15 6-methyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-chloro-4-methyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-formyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-acetyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-acetyl-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;  
20 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;  
4-acetyl-6-fluoro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-acetyl-6-methyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-propionyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
25 6-chloro-4-propionyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-benzoyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-chloro-4-methylsulphinyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;  
30 6-chloro-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-chloro-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;  
6-fluoro-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-methyl-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-ethylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;



- 6-chloro-4-ethylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
3-hydroxyimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-chloro-3-hydroxyimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
3-hydroxyimino-6-methyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
5 3-methoxyimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-chloro-3-methoxyimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
3-methylimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-chloro-3-phenylimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
their stereoisomers; and  
10 pharmaceutically acceptable salts thereof.

The compounds of the present invention may prepared and formulated into pharmaceutical formulations as described in WO94/11360.

- 15 The compound of formula I may be administered in any of the known pharmaceutical dosage forms. The amount of the compound to be administered will depend on a number of factors including the age of the patient, the severity of the condition and the past medical history of the patient and always lies within the sound discretion of the administering physician but it is generally envisaged that the dosage  
20 of the compound to be administered will be in the range 0.1 to 1000 mg preferably 1 to 500 mg per day given in one or more doses.

- Oral dosage forms are the preferred compositions for use in the present invention and these are the known pharmaceutical forms for such administration, for  
25 example tablets, capsules, granules, syrups and aqueous or oil suspensions. The excipients used in the preparation of these compositions are the excipients known in the pharmacist's art. Tablets may be prepared from a mixture of the active compound with fillers, for example calcium phosphate; disintegrating agents, for example maize starch; lubricating agents, for example magnesium stearate; binders,  
30 for example microcrystalline cellulose or polyvinylpyrrolidone and other optional ingredients known in the art to permit tableting the mixture by known methods. The tablets may, if desired, be coated using known methods and excipients which may include enteric coating using for example hydroxypropylmethylcellulose phthalate. The tablets may be formulated in a manner known to those skilled in the art so as to

give a sustained release of the compounds of the present invention. Such tablets may, if desired, be provided with enteric coatings by known methods, for example by the use of cellulose acetate phthalate. Similarly, capsules, for example hard or soft gelatin capsules, containing the active compound with or without added excipients, may be prepared by known methods and, if desired, provided with enteric coatings in a known manner. The contents of the capsule may be formulated using known methods so as to give sustained release of the active compound. The tablets and capsules may conveniently each contain 1 to 500 mg of the active compound. Preferably the tablets and capsules each contain 5, 10, 15, 20, 25, 30, 50, 100, 250 or 500mg.

Other dosage forms for oral administration include, for example, aqueous suspensions containing the active compound in an aqueous medium in the presence of a non-toxic suspending agent such as sodium carboxy-methylcellulose, and oily suspensions containing a compound of the present invention in a suitable vegetable oil, for example arachis oil. The active compound may be formulated into granules with or without additional excipients. The granules may be ingested directly by the patient or they may be added to a suitable liquid carrier (for example, water) before ingestion. The granules may contain disintegrants, eg an effervescent couple formed from an acid and a carbonate or bicarbonate salt to facilitate dispersion in the liquid medium.

The therapeutically active compounds of formula I may be formulated into a composition which the patient retains in his mouth so that the active compound is administered through the mucosa of the mouth.

Dosage forms suitable for rectal administration are the known pharmaceutical forms for such administration, for example, suppositories with cocoa butter or polyethylene glycol bases.

Dosage forms suitable for parenteral administration are the known pharmaceutical forms for such administration, for example sterile suspensions or sterile solutions in a suitable solvent.

Dosage forms for topical administration may comprise a matrix in which the pharmacologically active compounds of the present invention are dispersed so that the compounds are held in contact with the skin in order to administer the compounds transdermally. A suitable transdermal composition may be prepared by  
5 mixing the pharmaceutically active compound with a topical vehicle, such as a mineral oil, petrolatum and/or a wax, e.g. paraffin wax or beeswax, together with a potential transdermal accelerant such as dimethyl sulphoxide or propylene glycol. Alternatively the active compounds may be dispersed in a pharmaceutically acceptable cream, gel or ointment base. The amount of active compound contained  
10 in a topical formulation should be such that a therapeutically effective amount of the compound is delivered during the period of time for which the topical formulation is intended to be on the skin.

The therapeutically active compound of formula I may be formulated into a  
15 composition which is dispersed as an aerosol into the patients oral or nasal cavity. Such aerosols may be administered from a pump pack or from a pressurised pack containing a volatile propellant.

The therapeutically active compounds of formula I used in the method of the  
20 present invention may also be administered by continuous infusion either from an external source, for example by intravenous infusion or from a source of the compound placed within the body. Internal sources include implanted reservoirs containing the compound to be infused which is continuously released for example by osmosis and implants which may be (a) liquid such as an oily suspension of the  
25 compound to be infused for example in the form of a very sparingly water-soluble derivative such as a dodecanoate salt or a lipophilic ester or (b) solid in the form of an implanted support, for example of a synthetic resin or waxy material, for the compound to be infused. The support may be a single body containing all of the compound or a series of several bodies each containing part of the compound to be  
30 delivered. The amount of active compound present in an internal source should be such that a therapeutically effective amount of the compound is delivered over a long period of time.

In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.

5           The pharmaceutical compositions containing a therapeutically effective amount of a compound of Formula I may be used to treat obesity and related conditions including eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress in mammals particularly humans, and as an aid to smoking cessation in  
10 human beings. Whilst the precise amount of active compound administered in such treatment will depend on a number of factors, for example the age of the patient, the severity of the condition and the past medical history, and always lies within the sound discretion of the administering physician, the amount of active compound administered per day is in the range 1 to 1000 mg preferably 5 to 500 mg given in  
15 single or divided doses at one or more times during the day.

In yet another aspect, the present invention provides the use of a compound of Formula I in the manufacture of a medicament for use in the treatment of obesity and related conditions including eating disorders such as bulimia, anorexia, snacking  
20 and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, and as an aid to smoking cessation.

The present invention also provides a method of treating obesity and related conditions including eating disorders such as bulimia, anorexia, snacking and binge  
25 eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia and stress which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.

The present invention also provides a method of reducing the craving to  
30 smoke in human beings which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof. The present invention also provides a method of reducing weight gain after smoking cessation in human beings which comprises the administration of a therapeutically effective amount of a compound of Formula I to a patient in need thereof.

In addition the compounds of the present invention may be useful in the treatment or prevention of metabolic diseases and conditions arising therefrom, for example non exercise activity thermogenesis and increased metabolic rate.

5

The compounds of the present invention may be useful in preventing cardiovascular disease, and in reducing platelet adhesiveness, in aiding weight loss after pregnancy and in aiding weight loss after smoking cessation.


10

The following *in vivo* test supports the finding that compounds of formula I have efficacy in the treatment of obesity.

Marmosets given 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine (50 mg/kg po) daily for 14 days showed reduced bodyweight gain.

Claims

- 1) A method of treating obesity and related conditions comprising the administration to a mammal, particularly a human, in need thereof of a therapeutically effective amount of a compound of formula I



in which:

- 10  $n = 0, 1$  or  $2$ ;  
 $R_1$ , and  $R_2$  independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo);  
 $R_3$  and  $R_4$  independently represent H or alkyl of 1 to 4 carbon atoms; or together represent a group of formula  $=NR_{12}$  where  $R_{12}$  represents H, hydroxy, alkyl of 1 to 4 carbon atoms, phenyl or alkoxy of 1 to 4 carbon atoms; each alkyl, phenyl and alkoxy being optionally substituted with one or more halo;  
 15  $R_5$  represents: (a) H, (b) alkyl of 1 to 4 carbon atoms, (c) a group of formula  $-COR_{13}$  in which  $R_{13}$  represents H, alkyl of 1 to 4 carbon atoms or phenyl, when  $R_3$  and  $R_4$  represent H or alkyl (optionally substituted with one or more halo, or (d) or a group of formula  $-S(O)_pR_{14}$  in which  $p = 1$  or  $2$  and  $R_{14}$  is alkyl of 1 to 4 carbon atoms or phenyl, when  $R_3$  and  $R_4$  represent H or alkyl (optionally substituted with one or more halo); each alkyl and phenyl being optionally substituted with one or more halo;  
 $R_6$  and  $R_7$  are each H;  
 $R_8$  to  $R_{11}$  independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphonamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and
- 25

pharmaceutically acceptable salts thereof;

with the proviso that:

(i) when  $n = 0$ ; at least one of  $R_1$  to  $R_{11}$  is other than H;

together with a pharmaceutically acceptable diluent or carrier.

5

2) A method as claimed in claim 1 in which comprises a compound of formula I in which

$n$  is 0 or 1;

$R_1$ ,  $R_2$ ,  $R_6$  and  $R_7$  are each H;

10  $R_3$  and  $R_4$  are independently H or methyl; or together represent imino, methylimino, phenylimino, hydroxyimino or methoxyimino;

$R_5$  is H or methyl, or when  $R_3$  and  $R_4$  are independently H or methyl,  $R_5$  is H, methyl, formyl, acetyl, propionyl, benzoyl, methylsulphinyl, methylsulphonyl or ethylsulphonyl;

15  $R_8$  is H, methyl, fluoro or chloro; and

$R_9$ ,  $R_{10}$  and  $R_{11}$  are each H;

or a pharmaceutically acceptable salt thereof.

20 3) A method as claimed in claim 1 in which the compound of formula I is selected from:

6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;

6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;

6-fluoro-2,3,4,5-tetrahydro-1,4-benzothiazepine;

4-formyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;

25 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;

4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;

4-acetyl-6-fluoro-2,3,4,5-tetrahydro-1,4-benzothiazepine;

6-chloro-4-methylsulphinyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;

4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;

30 4-ethylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;

6-chloro-3-hydroxyimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;

3-hydroxyimino-6-methyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;

3-methylimino-2,3,4,5-tetrahydro-1,4-benzothiazepine; and

6-chloro-3-phenylimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;

their stereoisomers; and pharmaceutically acceptable salts thereof.

4) A method as claimed in claim 1 in which the compound of formula I is selected from:

- 5 6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;  
6-fluoro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-formyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
10 6-chloro-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-chloro-3-hydroxyimino-2,3,4,5-tetrahydro-1,4-benzothiazepine; and  
6-chloro-3-phenylimino-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
their stereoisomers; and pharmaceutically acceptable salts thereof.

15 5) A method as claimed in claim 1 in which the compound of formula I is selected from:

- 4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide;  
4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
20 6-chloro-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
6-chloro-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine 1-oxide; and  
6-fluoro-4-methylsulphonyl-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
their stereoisomers; and pharmaceutically acceptable salts thereof.

25 6) A method as claimed in claim 1 in which the compound of formula I is selected from:

4-acetyl-6-chloro-2,3,4,5-tetrahydro-1,4-benzothiazepine;  
and pharmaceutically acceptable salts thereof.

30 7) The use of a compound of Formula I as described in any one of claims 1-6 in the manufacture of a medicament for use in the treatment of obesity and related conditions including eating disorders such as bulimia, anorexia, snacking and binge eating, non-insulin dependent diabetes mellitus, hyperglycaemia, hyperlipidaemia, and stress, and as an aid to smoking cessation.



(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
4 January 2001 (04.01.2001)

PCT

(10) International Publication Number  
**WO 01/00185 A3**

- (51) International Patent Classification<sup>7</sup>: **A61K 31/554**,  
A61P 3/04, 3/06, 3/10, 25/34, 43/00
- (21) International Application Number: **PCT/EP00/05541**
- (22) International Filing Date: **16 June 2000 (16.06.2000)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:  
9914745.6                      24 June 1999 (24.06.1999)    **GB**
- (71) Applicant (for all designated States except US): **KNOLL GMBH [DE/DE]; D-67061 Ludwigshafen (DE).**
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **KILPATRICK, Ian, Charles [GB/GB]; R3 Pennyfoot Street, Nottingham NG1 1GF (GB).**
- (74) Agent: **NASH, David, Allan; Haseltine Lake & Co., Imperial House, 15-19 Kingsway, London WC2B 6UD (GB).**
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**
- Published:  
— with international search report
- (88) Date of publication of the international search report:  
**11 April 2002**
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **1,4-DENZOTHIAZEPINES TO TREAT OBESITY RELATED DISORDERS**

(57) Abstract: The present invention provides a method of treating obesity and related conditions such as bulimia, anorexia, snacking, binge eating, non insulin dependent diabetes mellitus, hyperglycaemia, stress, hyperlipidaemia, and to aid to smoking cessation comprising the administration to a mammal, particularly a human, in need thereof of a therapeutically effective amount of a compound of formula (I) in which:  $n=0, 1$  or  $2$ ;  $R_1$  and  $R_2$  independently represent H or alkyl of 1 to 4 carbon atoms (optionally substituted by one or more halo);  $R_3$  and  $R_4$  independently represent H or alkyl of 1 to 4 carbon atoms; or together represent a group of formula  $=NR_{12}$  where  $R_{12}$  represents H, hydroxy, alkyl of 1 to 4 carbon atoms, a phenyl or alkoxy of 1 to 4 carbon atoms; each alkyl, phenyl and alkoxy being optionally substituted with one or more halo;  $R_5$  represents: (a) H, (b) alkyl of 1 to 4 carbon atoms, (c) a group of formula  $-COR_{13}$  in which  $R_{13}$  represents H, alkyl of 1 to 4 carbon atoms or phenyl, when  $R_3$  and  $R_4$  represent H or alkyl (optionally substituted with one or more halo, or (d) a group of formula  $-S(O)_pR_{14}$  in which  $p=1$  or  $2$  and  $R_{14}$  is alkyl of 1 to 4 carbon atoms or phenyl, when  $R_3$  and  $R_4$  represent H or alkyl (optionally substituted with one or more halo); each alkyl and phenyl being optionally substituted with one or more halo;  $R_6$  and  $R_7$  are each H;  $R_8$  to  $R_{11}$  independently represent H, halo, cyano, nitro, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, carboxy, alkanoyloxy of 1 to 4 carbon atoms, carbamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms), or sulphamoyl (optionally substituted with alkyl of 1 to 4 carbon atoms); each alkyl, alkoxy, alkanoyl or alkanoyloxy optionally substituted with one or more halo; their stereoisomers; and pharmaceutically acceptable salts thereof.

WO 01/00185 A3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/05541

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/554 A61P3/04 A61P3/06 A61P3/10 A61P25/34  
A61P43/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, WPI Data, PAJ, EPO-Internal, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 11360 A (THE BOOTS COMPANY) 26 May 1994 (1994-05-26) cited in the application the whole document ---	1-7
A	EP 0 444 924 A (SUNTORY LIMITED) 4 September 1991 (1991-09-04) abstract page 2, line 6 ---	1-7
A	US 3 361 760 A (KRAPCHO J.) 2 January 1968 (1968-01-02) column 2, line 5 ---	1,7
A	US 5 610 153 A (BÜHLMAYER P. ET AL.) 11 March 1997 (1997-03-11) column 2 lines 41-47 and 57 ---	1-7
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

17 December 2001

Date of mailing of the international search report

21/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gac, G

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/05541

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 & JP 05 271208 A (KIRIN BREWERY CO LTD), 19 October 1993 (1993-10-19) abstract ---	1,7
A	WO 99 09991 A (KAKEN PHARMACEUTICAL CO LTD) 4 March 1999 (1999-03-04) page 9 -page 10 page 18, line 13 - line 20 page 28, line 37 - line 38 page 29 lines 9-12 and 37 page 30, line 2 - line 7 ---	1-7
X	EP 0 864 582 A (HOECHST AG) 16 September 1998 (1998-09-16) the whole document ---	7
X	WO 96 05188 A (THE WELLCOME FOUNDATION LIMITED) 22 February 1996 (1996-02-22) the whole document ---	7
X	US 5 817 652 A (BRIEADDY ET AL.) 6 October 1998 (1998-10-06) the whole document ---	7
X	US 5 723 458 A (BRIEADDY ET AL.) 3 March 1998 (1998-03-03) the whole document ---	7
X	WO 93 16055 A (THE WELLCOME FOUNDATION LIMITED) 19 August 1993 (1993-08-19) the whole document ---	7
X	GB 1 181 571 A (QUIBB & SONS INC.) 18 February 1970 (1970-02-18) the whole document, especially page 2 line 39 ---	7
A	DD 65 402 A (WÜNSCH K.H.) 5 November 1969 (1969-11-05) the whole document ---	7
	---	
	-/--	

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/05541

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBASE 'Online! ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; "Antihyperlipidaemic benzothiazepines" retrieved from DIALOG Database accession no. 1994184809 XP002183519 abstract &amp; EXPERT OPINION ON THERAPEUTIC PATENTS_(EXPERT OPIN. THER. PAT._), 1994, 4/6 (717-718),  United Kingdom the whole document -----</p>	7

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-7 (all partially)

use of compounds of formula I in the manufacture of a medicament for the treatment of obesity and related conditions including bulimia, anorexia, snacking and binge eating

2. Claims: 1-7 (all partially)

Use of compounds of formula I in the manufacture of a medicament for the treatment of non-insulin dependent diabetes mellitus or hyperglycemia

3. Claims: 1-7 (all partially)

Use of compounds of formula I in the manufacture of a medicament for the treatment of hyperlipidemia

4. Claims: 1-7 (all partially)

Use of compounds of formula I in the manufacture of a medicament for the treatment of stress

5. Claims: 1-7 (all partially)

Use of compounds of formula I in the manufacture of a medicament as an aid for smoking cessation

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.2

Present claim 1 relates to an extremely large number of possible compounds. In fact, the claim contains so many variables and possible permutations that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claim impossible. Moreover the term "and related conditions" in claim 1 is neither sufficiently clear nor concise nor supported by the description. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely on the compounds of claims 2-6 and on obesity and conditions mentioned in claim 7.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/05541

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9411360	A	26-05-1994	AT 163927 T	15-03-1998
			AU 680639 B2	07-08-1997
			AU 5464494 A	08-06-1994
			BG 62519 B1	31-01-2000
			BG 99679 A	30-04-1996
			BR 9307387 A	31-08-1999
			CA 2148584 A1	26-05-1994
			CZ 9501176 A3	12-06-1996
			DE 69317436 D1	16-04-1998
			DE 69317436 T2	02-07-1998
			DK 667866 T3	25-05-1998
			WO 9411360 A1	26-05-1994
			EP 0667866 A1	23-08-1995
			ES 2113081 T3	16-04-1998
			FI 952204 A	08-05-1995
			GR 3026386 T3	30-06-1998
			HU 71819 A2	28-02-1996
			JP 8503202 T	09-04-1996
			NO 951797 A	24-05-1995
			NZ 257843 A	28-10-1996
			PL 308757 A1	21-08-1995
			RU 2115650 C1	20-07-1998
			SK 58895 A3	13-09-1995
			US 5580866 A	03-12-1996
EP 444924	A	04-09-1991	JP 2871811 B2	17-03-1999
			JP 3275673 A	06-12-1991
			DE 69115954 D1	15-02-1996
			DE 69115954 T2	23-05-1996
			EP 0444924 A1	04-09-1991
			US 5312625 A	17-05-1994
US 3361760	A	02-01-1968	NONE	
US 5610153	A	11-03-1997	AU 685768 B2	29-01-1998
			AU 5696794 A	04-07-1994
			CA 2151384 A1	23-06-1994
			WO 9413651 A1	23-06-1994
			EP 0673371 A1	27-09-1995
			FI 952803 A	07-06-1995
			HU 72330 A2	29-04-1996
			JP 8505374 T	11-06-1996
			NO 952288 A	09-06-1995
			NZ 258889 A	24-02-1997
JP 05271208	A	19-10-1993	JP 3093419 B2	03-10-2000
WO 9909991	A	04-03-1999	AU 9025798 A	16-03-1999
			CN 1275912 T	06-12-2000
			EP 1021190 A1	26-07-2000
			JP 2001513565 T	04-09-2001
			WO 9909991 A1	04-03-1999
EP 864582	A	16-09-1998	EP 0864582 A2	16-09-1998
			AU 731575 B2	05-04-2001
			BR 9801126 A	21-03-2000
			CA 2231971 A1	14-09-1998
			CN 1194979 A ,B	07-10-1998

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC/EP 00/05541

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 864582	A	CZ 9800759 A3 HU 9800541 A2 IL 123648 A JP 10279568 A NZ 329932 A PL 325363 A1 TR 9800444 A2 US 6020330 A US 6114322 A ZA 9802140 A	16-09-1998 28-06-1999 21-11-2000 20-10-1998 28-01-1999 28-09-1998 21-10-1998 01-02-2000 05-09-2000 14-09-1998
WO 9605188	A 22-02-1996	AP 720 A AU 696073 B2 AU 4426096 A BG 62048 B1 BG 101209 A BR 9508586 A CA 2197099 A1 CN 1161035 A ,B CZ 9700373 A3 EE 9700028 A EP 0775126 A1 FI 970531 A WO 9605188 A1 HU 77129 A2 IL 114877 A JP 2935756 B2 JP 10504035 T NO 970585 A NZ 290911 A PL 318496 A1 SK 17797 A3	08-01-1999 03-09-1998 07-03-1996 29-01-1999 29-08-1997 14-07-1998 22-02-1996 01-10-1997 13-08-1997 15-08-1997 28-05-1997 07-02-1997 22-02-1996 02-03-1998 14-07-1999 16-08-1999 14-04-1998 07-04-1997 28-07-1998 23-06-1997 10-09-1997
US 5817652	A 06-10-1998	AT 158283 T AU 6007794 A CA 2156184 A1 DE 69405714 D1 DE 69405714 T2 DK 683773 T3 EP 0683773 A1 ES 2109672 T3 WO 9418183 A1 GR 3025532 T3 HU 71613 A2 JP 8507049 T ZA 9401000 A	15-10-1997 29-08-1994 18-08-1994 23-10-1997 29-01-1998 16-02-1998 29-11-1995 16-01-1998 18-08-1994 27-02-1998 29-01-1996 30-07-1996 15-08-1995
US 5723458	A 03-03-1998	AU 6008894 A CA 2156183 A1 EP 0683774 A1 WO 9418184 A1 HU 71610 A2 IL 108633 A JP 2886341 B2 JP 8506576 T ZA 9401003 A	29-08-1994 18-08-1994 29-11-1995 18-08-1994 29-01-1996 15-07-1998 26-04-1999 16-07-1996 14-08-1995
WO 9316055	A 19-08-1993	AT 178897 T	15-04-1999



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/05541

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 9316055	A	AU 675419 B2	06-02-1997	
		AU 3508293 A	03-09-1993	
		CA 2117485 A1	19-08-1993	
		DE 69324479 D1	20-05-1999	
		DE 69324479 T2	16-09-1999	
		DK 626952 T3	25-10-1999	
		EP 0626952 A1	07-12-1994	
		ES 2131106 T3	16-07-1999	
		FI 943775 A	16-08-1994	
		WO 9316055 A1	19-08-1993	
		GR 3030491 T3	29-10-1999	
		HK 1004217 A1	07-04-2000	
		HU 71487 A2	28-11-1995	
		IL 104740 A	12-09-1996	
		JP 2904926 B2	14-06-1999	
		JP 7503724 T	20-04-1995	
		KR 265529 B1	01-11-2000	
		MX 9300821 A1	01-09-1993	
		NZ 249189 A	27-02-1996	
		US 5663165 A	02-09-1997	
		US 5859240 A	12-01-1999	
		ZA 9301073 A	16-08-1994	
-----				
GB 1181571	A	18-02-1970	BE 695313 A	11-09-1967
			CH 482706 A	15-12-1969
			DE 1695698 A1	29-04-1971
			FR 7504 M	08-12-1969
			FR 1602881 A	08-02-1971
			NL 6703347 A	11-09-1967
			US 3794639 A	26-02-1974
-----				
DD 65402	A	NONE		
-----				